March 22, 2021 08:34 AM EDTUpdated 08:50 AM

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion

John Carroll

Editor & Founder

Last summer, San Diego-based Odonate $ODT CEO Kevin Tang enthusiastically sought to bolster investors’ enthusiasm for the company with what the biotech called “a potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion

John Carroll

Editor & Founder

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Those NDA plans Odonate had for mid-'21? They're be­ing scrapped — along with the en­tire biotech — in a sud­den im­plo­sion

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials